Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nemaura Medical Inc (NQ: NMRD )

0.1053 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nemaura Medical Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at H.C. Wainwright Bioconnect Conference
Via Investor Brand Network
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Marks True Milestone in Development, Growth
Via Investor Brand Network
Nemaura Medical Solutions Empowering People to Take Charge of Well-Being
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized... 
Via Benzinga
Nemaura Medical (NASDAQ: NMRD) Solutions Empowering People to Take Charge of Well-Being
Via Investor Brand Network
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Solutions to Empower People to Take Charge of Their Health, Well-Being
Via Investor Brand Network
Nemaura Medical Complete Initial Shipment of sugarBEAT(R) Devices to UK Licensee
Nemaura Medical announced the successful completion of its initial shipment of sugarBEAT(R) continuous glucose monitor devices to its UK licensee The initial shipment, which... 
Via Benzinga
Nemaura Medical (NASDAQ: NMRD) Complete Initial Shipment of sugarBEAT(R) Devices to UK Licensee
Via Investor Brand Network
Nemaura Medical Inc. (NASDAQ: NMRD) Complete Initial Shipment of sugarBEAT(R) Devices to UK Licensee
Via Investor Brand Network
Nemaura Medical Positioned to Benefit from Growth in CGM Market
Nemaura Medical (NASDAQ: NMRD) has developed a platform to monitor multiple chemicals in the blood without needles, replacing traditional invasive methods of diagnosis and health... 
Via Benzinga
Nemaura Medical (NASDAQ: NMRD) Positioned to Benefit from Growth in CGM Market
Via Investor Brand Network
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Positioned to Benefit from Growth in CGM Market
Via Investor Brand Network
54 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and... 
Via Benzinga
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Initial Shipment of CGM Devices to MySugarWatch Licensee
Via Investor Brand Network
Nemaura Medical Inc. (NASDAQ: NMRD) Helping Diabetic Individuals Safeguard Themselves From COVID-19
Via Investor Brand Network
Topics Death
Exposures COVID-19 Death
Nemaura Medical Releases Q2-2021 Results, Signs Global Commercial Contract
NMRD releases fiscal Q2-2021 results, provides business update Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2021
Upgrades According to William Blair, the prior rating for Graco Inc (NYSE: 
Via Benzinga
Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited
Via Investor Brand Network
Nemaura Medical CEO to Present at Upcoming Conference
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized... 
Via Benzinga
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) CEO to Present at Benzinga Global Small Cap Conference
Via Investor Brand Network
Nemaura Medical Offers 'First-of-a-Kind' Device in Growing CGM Market
The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028 The increasing prevalence of diabetes, rising focus on preventive care... 
Via Benzinga
Nemaura Medical Inc. (NASDAQ: NMRD) Offers ‘First-of-a-Kind’ Device in Growing CGM Market
Via Investor Brand Network
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2 2022 Financial, Business Report
Via Investor Brand Network
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2 2022 Financial, Business Report
Via Investor Brand Network
Nemaura Medical Inc. Extending Tech, Programs Beyond Traditional Diabetes Market
Nemaura Medical (NASDAQ: NMRD), a cutting-edge medical technology company, recently conducted the beta launch of MiBoKo, a new proprietary metabolic health program designed to... 
Via Benzinga
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Extending Proprietary Technology, Programs Beyond Traditional Diabetes Market
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nemaura Medical Inc. Announces Participation at Diabetes Technology Society Conference
Nemaura Medical (NASDAQ: NMRD) CEO Faz Chowdhury, PhD, will be presenting at annual meeting of the Diabetes Technology Society. The two-day meeting is slated for Nov. 5–6,... 
Via Benzinga
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Participation at Diabetes Technology Society Conference
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Stands Distinct in Patient Support
Via Investor Brand Network
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Facilitating Improved Diabetes and Prediabetes Management
Via Investor Brand Network
Nemaura Medical Inc. (NASDAQ: NMRD) Announce Beta Launch of Proprietary ‘MiBoKo’ Metabolic Health Program
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.